Abstract Library

#1939 Antiproliferative Effects of Lanreotide in Neuroendocrine Tumors

Introduction: Neuroendocrine tumors of the lung (BP-NETs, typical (AC) and atypical Carcinoids (ATC)) are rare tumors with heterogeneous behavior and molecular characteristics. For the intermediate proliferating BP-NETs treatment options are limited and unsatisfactory. Somatostatin analogues have not only anti-secretory effects, but also display antiproliferative features, as shown by PROMID and CLARINET trial. Nevertheless, their value in BP-NET is undefined so far.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Grabowski P

Authors: Lelek S, Sedding D, Benecke J, Siegmund B, Schrader J,

Keywords: Bronchopulmonary neuroendocrine tumors (BP-NET), somatostatin analogues, Lanreotide, signaling,

#1462 Cross-Talk Between EGFR and IGF1R Influences the Response to RTK Inhibitors in Bronchopulmonary (BP)-NET Cell Lines

Introduction: BP-NETs represent ~30% of all neuroendocrine tumors. BP-NET treatment is challenging due to onset of resistance to chemo and targeted therapies. EGFR and IGF1R had been associated with tumor onset and progression in several neoplasia.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Gagliano T

Authors: Gagliano T, Gentilin E, Benfini K, Falletta S, Di Pasquale C,

Keywords: BP-NET RTK,

#1298 Temozolomide-based Second-line Chemotherapy in Patients with Advanced Bronchopulmonary Neuroendocrine Tumours

Introduction: The management of advanced Bronchopulmonary Neuroendocrine Tumours (BP-NET) is not standardized. There are only few clinical studies of Temozolomide (TMZ) as monotherapy or in combination with other agents available for BP-NET.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Tabaksblat E, Ladekarl M,

Keywords: temozolomide, BP-NET, Ki-67 index,

#1039 Receptor Tyrosine-Kinases Inhibition: New Insights on Therapeutic Implications of EGFR and IGF1R in Human Bronchopulmonary NET

Introduction: The main treatment for bronchopulmonary NET(BP-NET) is surgery, which is not feasible for infiltrating and metastatic disease, where medical therapy is tried. Identifying new therapeutic targets is important to provide adequate medical treatment for patients with BP-NET. Sunitinib, a multi-targeted receptor tyrosine kinase inhibitor (TKI), is mainly described to inhibit VEGF

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Gagliano T

Authors: Gagliano T, Benfini K, Gentilin E, Falletta S, Di Pasquale C,

Keywords: RTK, BP-NET, IGF1R, EGFR,

#664 Natural Course and Survival of Thymic and Bronchopulmonary Neuroendocrine Tumors are Different for Male and Female MEN-1 Patients

Introduction: The course of thymic- and bronchopulmonary neuroendocrine tumors (Th- and Bp-NET) in MEN-1 patients is still unclear.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: De Laat J, Pieterman C, Twisk J, Hermus A, Dekkers O,

Keywords: MEN-1, lung NET, thymic NET, natural course, survival,